About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker ALC · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 12, 2026UNITY DX Cornea Study
NCT07768735 · Tomography
UNITY DX, ANTERION
ALC
Alcon Research
—Recruiting110Dec 2026Registry ↗
Nov 12, 2026An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness i…
NCT07578363 · Ocular Hyperemia
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preserv…
ALC
Alcon Research
Phase 3Recruiting178Nov 2026Registry ↗
Nov 12, 2026Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523 · Primary Open Angle Glaucoma
Hydrus Microstent, Cataract surgery
ALC
Alcon Research
Not applicableRecruiting545Oct 2028Registry ↗
Nov 10, 2026An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populatio…
NCT06538662 · Ocular Redness, Eye Irritation
Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
ALC
Alcon Research
Phase 3Completed284Jan 27, 2025Registry ↗
Nov 10, 2026A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular…
NCT06444529 · Ocular Redness
Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
ALC
Alcon Research
Phase 3Completed159Nov 14, 2024Registry ↗
Nov 9, 2026Contralateral Claims Study of Clareon Vivity Pro
NCT07484191 · Aphakia, Presbyopia
Clareon Vivity Pro IOL, Clareon Vivity IOL
ALC
Alcon Research
Not applicableActive, not recruiting165Oct 28, 2026Registry ↗
Nov 9, 2026Next Generation Rocklatan
NCT06441643 · Open Angle Glaucoma, Ocular Hypertension
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution
ALC
Alcon Research
Phase 2Completed646Nov 14, 2025Registry ↗
Oct 30, 2026Clareon TruPlus Study
NCT07502456 · Aphakia, Astigmatism
Clareon TruPlus Monofocal Non-Toric IOL, Clareon TruPlus Mo…
ALC
Alcon Research
Not applicableRecruiting185Jun 2028Registry ↗
Oct 30, 2026Capella Scientia Development Study
NCT06987474 · Cataract
Unity DX and SMARTCataract DX (SCDX) Biometer, IOLMaster 70…
ALC
Alcon Research
—Recruiting400May 2027Registry ↗
Oct 29, 2026Feasibility Study of an Accommodating IOL Design
NCT07147192 · Aphakia
AAL-FAIOL, BAL-FAIOL
ALC
Alcon Research
Not applicableTerminated
was active, not recruiting
17Oct 22, 2026Registry ↗
Oct 28, 2026Surgical Procedure Efficiency Evaluation stuDy
NCT07228091 · Cataract, Vitreous Hemorrhage
UNITY VCS, CONSTELLATION
ALC
Alcon Research
—Recruiting180Jun 2027Registry ↗
Oct 21, 2026Clinical Evaluation of a Novel Trifocal IOL
NCT07587138 · Aphakia, Cataract
LPYWT0, PXYWT0
ALC
Alcon Research
Not applicableRecruiting66Jul 2027Registry ↗
Oct 19, 2026Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
NCT07161635 · Aphakia, Presbyopia
Clareon PanOptix Pro/Pro Toric Trifocal IOL, Phacoemulsific…
ALC
Alcon Research
Not applicableCompleted110Oct 7, 2026Registry ↗
Oct 16, 2026Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
NCT07531043 · Ocular Hyperemia
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preserv…
ALC
Alcon Research
Phase 3Recruiting230Feb 2027Registry ↗
Oct 7, 2026Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops
NCT07540884 · Dry Eye Disease
Tears Naturale Free lubricating eye drops, Tears Naturale I…
ALC
Alcon Research
Not applicableCompleted132Sep 14, 2026Registry ↗
Sep 2, 2026Agreement of Two OCT Biometers: A Pilot Study
NCT07782619 · Anterior Segment of Eye, Axial Length
UNITY DX, ANTERION
ALC
Alcon Research
—Recruiting50Jan 2027Registry ↗
Sep 2, 2026Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
NCT05796453 · Aphakia, Astigmatism
Clareon Vivity IOL - Non Toric, Clareon Vivity IOL - Toric
ALC
Alcon Research
Not applicableCompleted470Aug 21, 2026Registry ↗
Sep 1, 2026Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design
NCT05317728 · Cataract
BAL-FAIOL IOL, Monofocal IOL
ALC
Alcon Research
Not applicableActive, not recruiting175Nov 2026Registry ↗
Aug 27, 2026Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153 · Neovascular Age-related Macular Degeneration (nAMD)
AR-14034 SR implant lower dose, AR-14034 SR implant higher…
ALC
Alcon Research
Phase 1/2Active, not recruiting139Apr 2027Registry ↗
Aug 25, 2026Clinical Investigation of a Femtosecond Laser for Corneal Flap Creation
NCT07036835 · Refractive Errors
LASIK Surgery, UV fs-Laser
ALC
Alcon Research
Not applicableCompleted128Aug 21, 2026Registry ↗
Aug 21, 2026Evaluation of Delefilcon A Contact Lenses
NCT06884202 · Refractive Errors, Myopia
Delefilcon A contact lenses with different base curves and…
ALC
Alcon Research
Not applicableCompleted267Aug 26, 2025Registry ↗
Aug 11, 2026An Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT07238699 · Dry Eye Disease
FID123440 test formulation, FID123437 test formulation
ALC
Alcon Research
Not applicableCompleted124Jul 22, 2026Registry ↗
Jul 28, 2026Clareon Toric Study (T2-T9)
NCT06285695 · Aphakia, Corneal Astigmatism
Clareon Toric IOL, Cataract surgery
ALC
Alcon Research
Not applicableCompleted129Jun 25, 2026Registry ↗
Jul 13, 2026Visual Performance With Clareon® Vivity® Intraocular Lenses (IOLs)
NCT06784063 · Astigmatism
Clareon Vivity Extended Vision IOL
ALC
Alcon Research
Not applicableCompleted40Jun 13, 2025Registry ↗
Jun 2, 2026Clareon PanOptix Pro vs. Clareon PanOptix - Study B
NCT06401551 · Aphakia, Presbyopia
CPO Pro IOL, CPO IOL
ALC
Alcon Research
Not applicableCompleted71Dec 13, 2024Registry ↗
Apr 21, 2026Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
NCT07082816 · Ocular Hypertension, Open Angle Glaucoma
Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Ne…
ALC
Alcon Research
Phase 3Completed489Apr 6, 2026Registry ↗
Mar 27, 2026A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
NCT06544694 · Dry Eye Disease
0.003% AR-15512 ophthalmic solution, Artificial Tears
ALC
Alcon Research
Phase 3Completed80Mar 21, 2025Registry ↗
Mar 23, 2026Evaluation of Long-term Safety and Performance of PanOptix Trifocal Intraocular Lens (IOL)
NCT06166901 · Aphakia, Astigmatism
AcrySof IQ PanOptix IOL Toric, AcrySof IQ PanOptix IOL Non-…
ALC
Alcon Research
Not applicableCompleted211Feb 5, 2025Registry ↗
Mar 17, 2026A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes
NCT06660290 · Dry Eye Disease
0.003% AR-15512 ophthalmic solution, Artificial tears
ALC
Alcon Research
Phase 3Completed55Feb 6, 2025Registry ↗
Feb 24, 2026Evaluation of Clareon Vivity/Vivity Toric
NCT05852470 · Aphakia
Clareon Vivity/Vivity Toric Extended Vision IOL, Clareon Mo…
ALC
Alcon Research
Not applicableCompleted155Oct 27, 2023Registry ↗
Feb 18, 2026Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease
NCT06444516 · Dry Eye Disease
FID123300 ocular lubricant
ALC
Alcon Research
Not applicableCompleted188Feb 7, 2025Registry ↗
Feb 10, 2026A Study Designed to Evaluate Tear Production
NCT06544707 · Dry Eye Disease
0.003% AR-15512 ophthalmic solution
ALC
Alcon Research
Phase 3Completed81Jan 30, 2025Registry ↗
Dec 24, 2025Clinical Performance Evaluation of Two Frequent Replacement Silicone Hydrogel Multifocal Toric Cont…
NCT06461455 · Presbyopia, Astigmatism
Lehfilcon A multifocal for astigmatism contact lenses, Samf…
ALC
Alcon Research
Not applicableCompleted95Dec 31, 2024Registry ↗
Dec 12, 2025UNITY VCS Vitreoretinal Surgery
NCT07054281 · Epiretinal Membrane, Macular Hole
UNITY Vitreoretinal Cataract System (VCS), CONSTELLATION Vi…
ALC
Alcon Research
Not applicableWithdrawn0Oct 2026Registry ↗
Dec 12, 2025A Cataract Surgery Clinical Trial
NCT07044674 · Cataract
UNITY Vitreoretinal Cataract System, CENTURION Vision Syste…
ALC
Alcon Research
Not applicableWithdrawn0May 2026Registry ↗
Dec 12, 2025Clareon PanOptix Pro vs. Clareon PanOptix - Study A
NCT06400745 · Aphakia, Presbyopia
CPO Pro IOL, CPO IOL
ALC
Alcon Research
Not applicableCompleted87Dec 13, 2024Registry ↗
Oct 9, 2025Clinical Performance of Two Frequent Replacement Silicone Hydrogel Multifocal Contact Lenses
NCT06469242 · Presbyopia
Serafilcon A multifocal contact lenses, Senofilcon A multif…
ALC
Alcon Research
Not applicableCompleted106Oct 8, 2024Registry ↗
Sep 16, 2025OPTI-FREE Family STUDY
NCT06592521 · Contact Lens Care
OPTI-FREE EXPRESS MPDS and Alcon contact lens case, OPTI-FR…
ALC
Alcon Research
Not applicableWithdrawn0Jan 2026Registry ↗
Sep 16, 2025AOSEPT (CLEAR CARE) PLUS Study
NCT06588400 · Contact Lens Care
AOSEPT Plus and AOCup lens case, AOSEPT Plus with HydraGlyd…
ALC
Alcon Research
Not applicableWithdrawn0Jan 2026Registry ↗
Sep 15, 2025Evaluation of AcrySof IQ Vivity Extended Vision Intraocular Lenses
NCT06541795 · Aphakia, Presbyopia
AcrySof IQ Vivity Extended Vision IOL
ALC
Alcon Research
Not applicableWithdrawn0Dec 2026Registry ↗
Aug 27, 2025Systane® Ultra Preservative Free Lubricant Eye Drops
NCT05902364 · Dry Eye
Systane Ultra PF lubricant eye drops
ALC
Alcon Research
Not applicableCompleted69Aug 14, 2024Registry ↗
Aug 17, 2025Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT06571656 · Dry Eye Disease
FID123359 test formulation, FID123360 test formulation
ALC
Alcon Research
Not applicableTerminated73Jul 11, 2025Registry ↗
Aug 14, 2025Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
NCT05886894 · Refractive Errors
Lotrafilcon B multifocal soft contact lenses, Comfilcon A m…
ALC
Alcon Research
—Completed351Jun 20, 2025Registry ↗
Aug 14, 2025Air Optix Extended Wear Contact Lenses
NCT05886881 · Refractive Errors
Lotrafilcon B spherical soft contact lenses, Lotrafilcon B…
ALC
Alcon Research
—Completed505Apr 15, 2025Registry ↗
Aug 14, 2025A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraoc…
NCT05799950 · Aphakia
AcrySof single-piece IOL, AcrySof multi-piece IOL
ALC
Alcon Research
—Completed138Jun 2, 2025Registry ↗
Jul 20, 2025DAILIES TOTAL1® Soft Contact Lenses - Post-Market Clinical Follow-up Study
NCT06483113 · Myopia, Hyperopia
Delefilcon A spherical soft contact lenses, Delefilcon A to…
ALC
Alcon Research
—Terminated192Feb 27, 2025Registry ↗
Jul 20, 2025Post-market Clinical Follow-up Study of Alcon PRECISION1™ Spherical and PRECISION1™ for Astigmatism…
NCT06462456 · Refractive Errors
Verofilcon A spherical soft contact lenses, Verofilcon A to…
ALC
Alcon Research
—Terminated140Mar 11, 2025Registry ↗
Jul 20, 2025Post-market Clinical Follow-up Study of Alcon TOTAL30® Contact Lenses (Lehfilcon A)
NCT06408649 · Ametropia, Myopia
Lehfilcon A spherical contact lenses, Lehfilcon A toric con…
ALC
Alcon Research
—Terminated129Apr 22, 2025Registry ↗
Jun 25, 2025Next Generation Cataract and Vitreoretinal Surgery Study
NCT06165744 · Vitreoretinal Disease With or Without Cataracts
UNITY Vitreoretinal Cataract System, Posterior segment surg…
ALC
Alcon Research
Not applicableCompleted120May 23, 2024Registry ↗
Jun 12, 2025Cosmetic Contact Lenses Post-Market Clinical Follow-up Study
NCT06517316 · Cosmetic Appearance
Nelfilcon A plano cosmetic contact lenses
ALC
Alcon Research
Not applicableWithdrawn0Mar 2026Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:36 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances